The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 21, 2023

Filed:

Aug. 26, 2019
Applicants:

Hangzhou Converd Co., Ltd., Zhejiang, CN;

Yafei Hou, Mountain View, CA (US);

Inventors:

Fang Hu, Zhejiang, CN;

Yafei Hou, Mountain View, CA (US);

Jipo Sheng, Zhejiang, CN;

Xiankui Tan, Zhejiang, CN;

Assignees:

HANGZHOU CONVERD CO., LTD., Zhejiang, CN;

Other;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C12N 7/00 (2006.01); C07K 14/74 (2006.01); C07K 14/725 (2006.01); A61P 35/00 (2006.01); A61K 35/768 (2015.01); A61K 38/17 (2006.01); A61K 38/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 35/768 (2013.01); A61K 38/1774 (2013.01); A61K 38/28 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70539 (2013.01); C12N 7/00 (2013.01);
Abstract

A therapeutic agent comprising a nucleic acid and a TCR modified immune cell and use thereof. The therapeutic agent comprises a first composition comprising a first active ingredient and a second composition comprising a second active ingredient. The first active ingredient includes or contains a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell. The labeling polypeptide has one or more epitope polypeptides which can be presented on a surface of the tumor cell and/or cancer cell by MHC class I molecules. The second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier and the second active ingredient comprises a T cell receptor modified immune cell which can specifically recognize and bind to the epitope polypeptide presented by MHC class I molecules. The therapeutic agent achieves synergistic treatment effect and provides a new route for tumor treatment.


Find Patent Forward Citations

Hu, Fang. (2023). Therapeutic agents comprising nucleic acids and tcr modified immune cells and uses thereof (U.S. Patent No. 11819519). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11819519

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…